Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents

BACKGROUND: Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in development for the treatment of anemia secondary to chronic kidney disease. METHODS: In this open-label Phase 2 trial, vadadustat was evaluated in 94 subjec...

Descripción completa

Detalles Bibliográficos
Autores principales: Haase, Volker H, Chertow, Glenn M, Block, Geoffrey A, Pergola, Pablo E, deGoma, Emil M, Khawaja, Zeeshan, Sharma, Amit, Maroni, Bradley J, McCullough, Peter A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322440/
https://www.ncbi.nlm.nih.gov/pubmed/29672740
http://dx.doi.org/10.1093/ndt/gfy055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322440/
https://www.ncbi.nlm.nih.gov/pubmed/29672740
http://dx.doi.org/10.1093/ndt/gfy055

Ejemplares similares